Stock LIFE ATYR PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News aTyr Pharma, Inc.

Equities

LIFE

US0021202025

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-15 pm EDT 		5-day change 1st Jan Change
1.7 USD -2.30% Intraday chart for aTyr Pharma, Inc. -7.10% +20.57%
Mar. 15 RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier MT
Mar. 14 Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
ATyr Pharma to Participate in April Investor Conferences
AQ
RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier
MT
Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024
ATyr Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Atyr Pharma: Q4 Earnings Snapshot
AQ
ATyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
AQ
ATyr Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
ATyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
AQ
ATyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
AQ
ATyr Pharma, Inc. Announces Plans to Initiate an Individual Patient Expanded Access Program for Its Lead Therapeutic Candidate, Efzofitimod, for Patients with Pulmonary Sarcoidosis
CI
ATyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
AQ
ATyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
AQ
ATyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
AQ
ATyr Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Atyr Pharma: Q3 Earnings Snapshot
AQ
ATyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
AQ
Earnings Flash (LIFE) ATYR PHARMA Posts Q3 Revenue $353,000
MT
ATyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT Study of Efzofitimod in Patients with SSc-ILD
AQ
ATyr Pharma to Present at November Investor Conferences
AQ
ATyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LIFE Stock
  4. News aTyr Pharma, Inc.